Summary of Terns Pharmaceuticals Conference Call Company Overview - Terns Pharmaceuticals, founded in 2017, focuses on precision oncology, specifically developing small molecule TERN-701 for chronic myeloid leukemia (CML) [3][4] - TERN-701 has shown unprecedented efficacy, demonstrating 2-3 times the efficacy compared to other agents with a differentiated safety profile [3][12] Industry Context - The chronic myeloid leukemia (CML) market has a significant unmet need, particularly in patients who do not achieve major molecular response (MMR) [5][4] - Current treatments, including imatinib and asciminib, have limitations, with over 75% of patients not responding adequately to the best available therapies [5][6] Key Findings from Recent Data - TERN-701 achieved a 75% MMR in patients at doses of 320 mg and above, with deep molecular response rates exceeding 30% [11][12] - The safety profile of TERN-701 is favorable, with low rates of cytopenias and no significant adverse events compared to asciminib [12][13] - TERN-701 has shown efficacy in asciminib-refractory patients, a critical indicator of its potential superiority [15][27] Competitive Landscape - Asciminib has gained approximately 25% market share in the frontline setting, with expectations to reach 50% [6][7] - TERN-701 is positioned as a potential best-in-disease drug due to its efficacy, safety, and lack of food effect, which is crucial for patient adherence [27][40] - The company anticipates that TERN-701 will outperform asciminib in frontline settings, where newly diagnosed patients are generally easier to treat [32][40] Development Plans - Terns Pharmaceuticals plans to conduct a registrational study for TERN-701 in a second-line plus population, with a control arm of a physician's choice 2GTKI [84][86] - A frontline study is also planned, potentially comparing TERN-701 against imatinib or asciminib [86][88] - The company aims to finalize dose selection and engage with the FDA for guidance on study design by mid-2026 [43][82] Financial Position - Terns Pharmaceuticals has secured funding that positions it well for commercialization and launch of TERN-701 in the second-line plus setting [93][94] Additional Insights - The absence of a food effect with TERN-701 is a significant advantage, as many patients struggle with dietary restrictions associated with other therapies [49][55] - The company is exploring a mutation-specific cohort in its studies to address patients with specific genetic mutations, such as T315I [66][72] Conclusion - Terns Pharmaceuticals is poised to make a significant impact in the CML treatment landscape with TERN-701, addressing critical unmet needs and positioning itself against established therapies like asciminib and imatinib. The upcoming studies and FDA interactions will be pivotal in shaping the future of TERN-701 in the market [40][93]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $5.1 million, a significant increase from $0.3 million in Q4 2024, primarily driven by net YCANTH revenue of $3.7 million and $1.4 million from Torii collaboration revenue [25][26] - Full year 2025 total revenue reached $35.6 million, up 368% from $7.6 million in 2024, with net YCANTH revenue of $15.3 million and $20.3 million from Torii collaboration [26] - Gross product margins improved to 85.7% for 2025 compared to 71.8% in the prior year [26] Business Line Data and Key Metrics Changes - YCANTH revenue grew by over 130% compared to 2024, with Q4 2025 revenue at $3.7 million, reflecting a 3.2% increase from Q3 2025 [11][25] - Dispensed applicator units for YCANTH increased to 51,196 in 2025, a 99% growth from 25,773 units in 2024 [13] - In Q4 2025, dispensed applicator units grew to 13,654, a 58% increase from Q4 2024, although there was a 3% decrease from Q3 2025 [12] Market Data and Key Metrics Changes - The company is expanding its market presence in Europe, with positive feedback from the European Medicines Agency regarding the marketing authorization application for YCANTH [15][16] - The common warts market is estimated to have over 20 million patients in the U.S., significantly larger than the molluscum market, which has about 6 million patients [77] Company Strategy and Development Direction - The company aims to establish YCANTH as the new standard of care for molluscum contagiosum and is pursuing label expansion to include common warts [7][10] - The company has strengthened its financial position through a $50 million equity raise and non-dilutive funding from Torii, extending its cash runway into 2027 [9][23] - The company is focused on optimizing its commercial strategy and expanding its product portfolio, including advancing VP-315 for basal cell carcinoma [5][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the transformation of the business and the foundation laid for long-term value creation [5][36] - The company is excited about the potential of its pipeline programs and the expected growth in the commercial business [9][36] Other Important Information - The company reported a GAAP net loss of $8.1 million for Q4 2025, an improvement from a loss of $16.2 million in Q4 2024 [32] - The company has eliminated all outstanding debt following a $35 million payment to settle obligations under its credit agreement [31] Q&A Session Summary Question: What initiatives are in place to broaden the YCANTH launch? - Management is focusing on simplifying patient and physician acquisition processes and is seeing early growth from the YcanthRx program [40][41] Question: What partnerships are being considered for EU expansion? - The company is exploring partnerships to enhance access to YCANTH for patients and caregivers in Europe [49] Question: How is the competitive landscape with ZELSUVMI? - Management views the presence of competitors as validation of demand for treatments and remains confident in YCANTH's value proposition [50][51] Question: What is the target prescriber base for YCANTH? - The focus will be on pediatricians and dermatologists, with an emphasis on optimizing targeting and segmentation [55][57] Question: What is the status of insurance coverage for YCANTH? - Coverage wins have been achieved in both Medicaid and commercial segments [58] Question: What is the estimated cost for the VP-315 phase III program? - The company is still assessing costs and aims to run the program efficiently, with favorable feedback from the FDA on the study design [62] Question: How does the common warts opportunity compare to molluscum? - The common warts market is significantly larger, with an estimated 20 million patients compared to 6 million for molluscum [77]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $5.1 million, a significant increase from $0.3 million in Q4 2024, primarily driven by net YCANTH revenue of $3.7 million and $1.4 million from Torii collaboration revenue [25] - Full year 2025 total revenue reached $35.6 million, up 368% from $7.6 million in 2024, with net YCANTH revenue of $15.3 million and $20.3 million from Torii collaboration [26] - Gross product margins for 2025 were 85.7%, compared to 71.8% in the prior year [26] Business Line Data and Key Metrics Changes - YCANTH revenue grew by over 130% compared to 2024, with Q4 2025 revenue at $3.7 million, reflecting a 3.2% increase from Q3 2025 [11][25] - Dispensed applicator units for YCANTH grew to 51,196 in 2025, a 99% increase from 25,773 units in 2024 [13] - In Q4 2025, YCANTH's dispensed applicator units increased by 58% compared to Q4 2024, although there was a slight decrease of approximately 3% from Q3 2025 [12] Market Data and Key Metrics Changes - The company is expanding its market presence in Europe, with positive feedback from the European Medicines Agency regarding the marketing authorization application for YCANTH [15][16] - The common warts program is expected to address a larger patient population, with an estimated 20 million patients in the U.S. compared to 6 million for molluscum [77] Company Strategy and Development Direction - The company aims to establish YCANTH as the new standard of care for molluscum contagiosum and is pursuing label expansion to include common warts [5][36] - The company has implemented a more optimized commercial strategy, resulting in a significant reduction in selling, general, and administrative expenses by over 40% [7][30] - The company is focused on advancing its pipeline, including the common warts and basal cell carcinoma programs, with plans for phase 3 trials [9][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the transformation of the business and the foundation for long-term value creation for shareholders [5][36] - The company is preparing for a phase 3-ready program in basal cell carcinoma and has extended its cash runway into 2027 [23][34] Other Important Information - The company executed a $50 million equity raise in November 2025, which allowed for the retirement of outstanding debt [9][23] - The company reported a GAAP net loss of $8.1 million for Q4 2025, a significant improvement from a loss of $16.2 million in Q4 2024 [32] Q&A Session Summary Question: What initiatives do you have in mind to broaden the YCANTH launch? - Management is focusing on simplifying patient and physician acquisition of the product and is seeing early growth in the YcanthRx program [38][40] Question: What kind of partnerships might you be looking into around expansion into the EU? - The company is exploring partnerships to bring YCANTH to patients in need and is advancing registration activities in Europe [47][49] Question: How much of the TAM or how many molluscum prescribers do you plan to target with this size team? - The company plans to continue expanding into the pediatrician space while refining targeting in dermatology [54][55] Question: What are the coverage wins in 2025 and 2026? - Coverage wins include enhancements in both Medicaid and commercial segments [58] Question: What is the estimated cost for the phase 3 program for VP-315? - The company is still assessing costs and aims to run the program as efficiently as possible [62] Question: How does the common warts opportunity compare to the molluscum opportunity? - The common warts market is estimated to be three times larger than that of molluscum, with a significant prescriber base overlap [77][79]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $5.1 million, a significant increase from $0.3 million in Q4 2024, primarily driven by net YCANTH revenue of $3.7 million and $1.4 million from Torii collaboration revenue [24] - Full year 2025 total revenue reached $35.6 million, up 368% from $7.6 million in 2024, with net YCANTH revenue of $15.3 million and $20.3 million from Torii collaboration [25] - Gross product margins for 2025 were 85.7%, compared to 71.8% in the prior year [25] Business Line Data and Key Metrics Changes - YCANTH revenue grew by over 130% compared to 2024, with Q4 2025 revenue of $3.7 million, reflecting a 3.2% increase from Q3 2025 [5][9] - Dispensed applicator units for YCANTH grew to 51,196 in 2025, a 99% increase from 25,773 units in 2024 [11] - In Q4 2025, YCANTH's dispensed applicator units increased by 58% compared to Q4 2024, although there was a slight decrease of approximately 3% from Q3 2025 [10] Market Data and Key Metrics Changes - The company is expanding its market presence in Europe, with positive feedback from the European Medicines Agency regarding the marketing authorization application for YCANTH [15] - The common warts market is estimated to have over 20 million patients in the U.S., significantly larger than the molluscum market, which has about 6 million patients [76] Company Strategy and Development Direction - The company aims to establish YCANTH as the new standard of care for molluscum contagiosum and is executing a label expansion strategy for common warts [4][35] - The company has strengthened its financial position through a $50 million equity raise and eliminated outstanding debt, extending its cash runway into 2027 [22][33] - The company is advancing its clinical programs for common warts and basal cell carcinoma, with a focus on efficient trial designs and potential partnerships for commercialization [20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the transformation of the business in 2025 and the potential for significant growth in 2026 [4][35] - The management noted that the largest competitor in the molluscum market is "watchful waiting," indicating a strong opportunity for YCANTH [49] - The company is excited about the potential of VP-315 as a non-surgical immunotherapy for basal cell carcinoma, aiming to change treatment paradigms [79] Other Important Information - The company has made significant investments in its co-pay assistance program to improve patient access to YCANTH [9] - The company is actively exploring non-dilutive funding opportunities for its clinical programs [22] Q&A Session Summary Question: What initiatives do you have in mind to broaden the YCANTH launch? - Management is seeing early growth in the YcanthRx program and aims to simplify patient and physician acquisition of the product [39] Question: What kind of partnerships might you be looking into around expansion into the EU? - The company is exploring partnerships to bring YCANTH to patients in need and provide access to caregivers [46] Question: How much of the TAM or how many molluscum prescribers do you plan to target with this size team? - The focus will continue on pediatricians while refining targeting in dermatology, with an emphasis on both specialties [53] Question: Can you help us think about the seasonality curve for YCANTH? - Historically, Q1 is slower, but recent investments in marketing and sales are showing positive trends [68] Question: What is the estimated cost for the VP-315 phase 3 program? - The company is still assessing costs and aims to run the program as efficiently as possible [60]

Summary of Esperion Therapeutics Conference Call Company Overview - **Company**: Esperion Therapeutics (NasdaqGM:ESPR) - **Industry**: Cardiovascular therapeutics - **Recent Performance**: Reported earnings with significant growth metrics Key Financial Highlights - **Total Revenue**: $408 million, representing a **38% year-over-year growth** [2] - **TRx Growth**: **34% year-over-year** and **11% quarter-over-quarter** growth in TRx [2] Acquisition Details - **Acquisition of Corstasis**: - Focused on a newly approved nasal loop diuretic, Enbumyst, which is **40 times more potent than furosemide** [3][6] - Expected to close in the **first week of April 2026** [3] - **Transaction Value**: $75 million upfront plus up to $180 million in milestones [18] - Financing through expanding existing term loan and monetizing Japanese royalties [19] Market Opportunity - **Target Markets**: - Expanding into cardiometabolic field, addressing unmet needs in heart failure [6][7] - Anticipated to reduce hospital readmission rates, which cost between **$12,000-$18,000** per heart failure readmission [13] - **Nasal Delivery System**: - Easy to use, potentially improving patient compliance and outcomes [14][16] Commercial Strategy - **Integration Plans**: - Pre-integration phase ongoing, with plans to leverage existing commercial infrastructure for product launch [23] - Focus on payer access and relationships with specialty pharmacies [30] - **Growth Strategy for Bempedoic Acid**: - Targeting **$1 billion plus opportunities** in the U.S. market [37] - Emphasis on maximizing NEXLIZET and NEXLETOL products [39] Competitive Landscape - **Guidelines and Market Position**: - Anticipation of new guidelines to provide a tailwind for bempedoic acid [37] - Highlighting unique outcomes data to differentiate from competitors [40][41] International Markets - **Partnerships**: - Strong performance reported by Daiichi Sankyo in Europe, particularly in Germany and the UK [57][61] - Otsuka in Japan showing promising sales, with over **700 representatives** promoting the drug [61] Future Outlook - **Vision 2040**: - Focus on growing the bempedoic acid franchise, business development, and pipeline expansion [78] - Upcoming clinical trials for ESP-2001 targeting primary sclerosing cholangitis [79] - Plans to explore kidney-related therapies, complementing heart failure treatments [80] Financial Health - **Cash Position**: - Ended the year with **$168 million** in cash, with ongoing improvements to the balance sheet [72] - Commitment to deleveraging while maintaining growth [75] Conclusion - Esperion Therapeutics is positioned for significant growth through strategic acquisitions, a robust product pipeline, and a strong commercial strategy aimed at addressing unmet needs in cardiovascular care. The company anticipates continued success in 2026, building on the momentum from 2025.

Summary of Nuvation Bio Conference Call Company Overview - **Company**: Nuvation Bio (NYSE:NUVB) - **Event**: 2026 Conference on March 11, 2026 Key Points on Ibtrozi Launch - **Launch Performance**: The Ibtrozi launch has been successful, treating 432 patients in the first two quarters, averaging over 200 patients per quarter, which is six times the initial performance of Augtyro [4][39] - **Sales Dynamics**: Sales have been successful across all territories with 47 sales representatives achieving success in various geographies [5] - **Lines of Therapy**: Majority of prescriptions are in later lines of therapy, typical for oncology launches, but there is a growing trend in first-line use [4][14] Patient Treatment Insights - **Duration of Therapy**: Progression-free survival in the first-line setting is approximately 46 months, decreasing significantly in later lines [9][11] - **Reimbursement Challenges**: Few reimbursement challenges have been reported, with only a small number of patients seeking assistance through the Nuvation Connect portal [12][14] - **Discontinuation Rates**: 75% of discontinuations are from third-line plus patients, indicating that earlier line patients are remaining on the drug longer [29] Financial Projections - **Sales Estimates**: The company is comfortable with a consensus estimate of just under $150 million for the first full year of sales, expecting growth to be non-linear [31][32] - **Gross to Net Dynamics**: The gross to net ratio was above 25% in the first quarter, with expectations for gradual improvement [38] Market Expansion Potential - **ROS1 Testing**: The market for ROS1 testing is expected to grow as RNA testing becomes standard, which is 30% more sensitive than DNA testing [41][42] - **NCCN Guidelines Impact**: Changes in NCCN guidelines are expected to increase ROS1 TKI use, as IO is now contraindicated [43][44] Competitive Landscape - **Comparison with Competitors**: Ibtrozi shows superior efficacy compared to Nuvalent's drug, with higher response rates and intracranial response rates [66][69] - **Adjuvant Plans**: Nuvation Bio is the only ROS1 TKI pursuing adjuvant studies, which could lead to significant market share [79][85] Safusidenib Development - **IDH1 Inhibitor**: Safusidenib shows promising results in low-risk, low-grade glioma, with a response rate of 44% compared to Vorasidenib's 11% [90] - **Future Studies**: Ongoing studies aim to expand approval across multiple glioma segments, with potential for approval based on response rates [91][96] Conclusion - Nuvation Bio is positioned strongly in the oncology market with Ibtrozi and Safusidenib, showing promising launch metrics, competitive advantages, and a clear path for future growth and market expansion.

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Soleno Therapeutics, Inc. regarding violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by May 5, 2026 [1][2] Group 1: Allegations Against Soleno Therapeutics - The complaint alleges that Soleno and its executives made false or misleading statements and failed to disclose significant safety concerns related to the Phase 3 clinical trial program for DCCR, including issues of excess fluid retention [1][2] - The administration of DCCR for treating hyperphagia in individuals with Prader-Willi syndrome (PWS) posed greater safety risks than disclosed, leading to lower commercial viability and undisclosed risks of adverse events post-launch [1][2] Group 2: Stock Price Impact - Following a critical report from Scorpion Capital on August 15, 2025, Soleno's stock price fell from over $77 per share to approximately $68 per share, a decline of nearly 12% over two trading days [1][2] - After a patient death was disclosed on September 10, 2025, the stock price dropped from more than $70 per share to about $57 per share, a decline of approximately 19% over two trading days [1][2] - On November 4, 2025, Soleno reported third-quarter financial results indicating that the earlier report disrupted the launch trajectory of DCCR, causing the stock price to decline from nearly $64 per share to approximately $47 per share, a one-day decline of about 27% [1][2]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, reminding investors of the April 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [1] Group 1: Legal Action and Allegations - The complaint alleges that Inovio and its executives violated federal securities laws by making false and/or misleading statements and failing to disclose deficiencies in the manufacturing of Inovio's CELLECTRA device [1] - It is claimed that Inovio is unlikely to submit the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 due to these deficiencies [1] - The company reportedly lacks sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [1] Group 2: Stock Market Impact - Following the FDA's announcement that it accepted Inovio's BLA for INO-3107 on a standard review timeline, Inovio's stock price fell by $0.56 per share, or 24.45%, closing at $1.73 per share on December 29, 2025 [1] Group 3: Class Action Participation - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will direct and oversee the litigation on behalf of the class members [1] - Any member of the putative class may move the Court to serve as lead plaintiff or choose to remain an absent class member, with their ability to share in any recovery unaffected by this decision [1]

Core Viewpoint - Ultragenyx Pharmaceutical Inc is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the efficacy of its drug setrusumab for Osteogenesis Imperfecta, leading to significant stock price declines after study failures were announced [1][2] Summary by Relevant Sections Legal Action - Faruqi & Faruqi, LLP is investigating claims against Ultragenyx and reminds investors of the April 6, 2026 deadline to seek lead plaintiff status in the class action lawsuit [1] - The lawsuit alleges that Ultragenyx executives misrepresented the reliability of information regarding setrusumab's effects and downplayed risks associated with the Phase III Orbit study [1][2] Study Results - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, resulting in a stock price drop of over 25% [1] - On December 29, 2025, Ultragenyx announced that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, causing a further stock price decline of more than 42% [2] Investor Information - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can choose to serve as lead plaintiff or remain an absent class member [2] - Faruqi & Faruqi encourages individuals with information about Ultragenyx's conduct to come forward, including whistleblowers and former employees [2]

Core Viewpoint - Clearmind Medicine Inc. is advancing its clinical trial for CMND-100, a non-hallucinogenic treatment for Alcohol Use Disorder (AUD), following positive results from previous cohorts [1][2][4]. Group 1: Clinical Trial Progress - The company is continuing participant enrollment for the third cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100 [1]. - The second cohort's results showed continued safety and tolerability, leading to unanimous approval from the Data and Safety Monitoring Board (DSMB) to proceed with the next phase [2]. - The trial is a multinational, multicenter study aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD [3]. Group 2: Company Insights - Clearmind Medicine focuses on developing novel, non-hallucinogenic therapeutics derived from neuroplastogens to address significant health issues, including AUD [5]. - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [6].